{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:26:54Z","timestamp":1776173214420,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["212981"],"award-info":[{"award-number":["212981"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lupus nephritis (LN), a severe organ manifestation of systemic lupus erythematosus (SLE), significantly impacts health-related quality of life (HRQoL). Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and Lupus Quality of Life (LupusQoL) have been validated to measure HRQoL in SLE, but not specifically in LN. Patient-reported symptoms of LN are not well-reported. We assessed the content validity and relevance of these measures in evaluating patients with LN and their LN-related experiences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This qualitative, interview-based study enrolled patients with LN from three US sites from a larger, retrospective survey study. The interview comprised an open-ended concept elicitation part and a more structured cognitive part. Concept elicitation was used to identify relevant themes describing the patients\u2019 experiences. Patients were asked to describe their LN-related symptoms, the severity and impact of those symptoms and their satisfaction with treatment. A cognitive interview approach evaluated the appropriate understanding of the items, instructions, and response options and asked patients about their understanding of the FACIT-Fatigue or LupusQoL measures, their relevance to the condition, and any aspects of confusion or need for better clarity of the questionnaires. All interviews were recorded and transcribed. The concept elicitation data were coded, while the cognitive interview data were tabulated to present the participants\u2019 responses next to the interview questions to support the evaluation of their understanding of the questionnaire items.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 10 patients participated in FACIT-Fatigue and another 10 in LupusQoL interviews; 18 patients were female, 10 were Black (self-reported) and 17 were receiving maintenance treatment for LN with stable disease activity. When patients recalled their symptoms, 670 expressions of varying symptoms were reported. All patients described pain, discomfort, and energy-related symptoms. Urinary frequency and non-joint swelling were most frequently attributed to LN rather than SLE. Patients felt the questions asked in the FACIT-Fatigue and LupusQoL surveys were relevant to their LN experience.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The symptoms reported by patients with LN were consistent with symptoms reported by the overall SLE population. However, patients indicated that some symptoms of LN were more profound than symptoms of SLE alone, affecting a broad range of areas of daily life activity and resulting in a higher burden on their HRQoL. FACIT-Fatigue and LupusQoL demonstrated content relevance as meaningful tools for patients with LN. However, further quantitative data collection is needed to ensure that these patient-reported outcome tools demonstrate good measurement properties in an LN population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00783-z","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T13:02:11Z","timestamp":1727701331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-reported outcome measures for lupus nephritis: content validity of LupusQoL and FACIT-Fatigue"],"prefix":"10.1186","volume":"8","author":[{"given":"Mona L.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer N.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deven","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6610-9709","authenticated-orcid":false,"given":"Wen-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Gairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"783_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fimmu.2019.00772","volume":"10","author":"AA Herrada","year":"2019","unstructured":"Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cuitino L, Llanos C (2019) Innate immune cells\u2019 contribution to systemic lupus erythematosus. Front Immunol 10:772. https:\/\/doi.org\/10.3389\/fimmu.2019.00772","journal-title":"Front Immunol"},{"key":"783_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, O\u2019Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarc\u00f3n GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55:252\u2013262. https:\/\/doi.org\/10.1093\/rheumatology\/kev311","journal-title":"Rheumatology (Oxford)"},{"key":"783_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1046\/j.1523-1755.2003.00289.x","volume":"64","author":"S Fukuhara","year":"2003","unstructured":"Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ, Worldwide Dialysis O, Practice Patterns S (2003) Health-related quality of life among dialysis patients on three continents: the Dialysis outcomes and practice patterns study. Kidney Int 64:1903\u20131910. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00289.x","journal-title":"Kidney Int"},{"key":"783_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM (2016) Risk of end-stage renal disease in patients with Lupus Nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68:1432\u20131441. https:\/\/doi.org\/10.1002\/art.39594","journal-title":"Arthritis Rheumatol"},{"key":"783_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012373960-5.00336-1","volume-title":"Epidemiology and Demography in Public Health","author":"R Hays","year":"2010","unstructured":"Hays RD, Reeve BB (2010) Measurement and modeling of health-related quality of life. Epidem Demog Public Health 1:195\u2013205. https:\/\/doi.org\/10.1016\/B978-012373960-5.00336-1"},{"key":"783_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1177\/09612033221100910","volume":"31","author":"S Kharawala","year":"2022","unstructured":"Kharawala S, Kaur G, Shukla H, Scott DA, Hawkins N, Chen WH, Gairy K (2022) Health-related quality of life, fatigue and health utilities in lupus nephritis: a systematic literature review. Lupus 31:1029\u20131044. https:\/\/doi.org\/10.1177\/09612033221100910","journal-title":"Lupus"},{"key":"783_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0961203313491849","volume":"22","author":"C Bexelius","year":"2013","unstructured":"Bexelius C, Wachtmeister K, Skare P, J\u00f6nsson L, Vollenhoven R (2013) Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus 22:793\u2013801. https:\/\/doi.org\/10.1177\/0961203313491849","journal-title":"Lupus"},{"key":"783_CR9","doi-asserted-by":"publisher","unstructured":"Chalhoub NE, Luggen ME (2022) Depression-, pain-, and health-related quality of life in patients with systemic lupus erythematosus. Int J Rheumatol 2022:6290736. https:\/\/doi.org\/10.1155\/2022\/6290736","DOI":"10.1155\/2022\/6290736"},{"key":"783_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrrheum.2009.106","volume":"5","author":"CS Lau","year":"2009","unstructured":"Lau CS, Mak A (2009) The socioeconomic burden of SLE. Nat Rev Rheumatol 5:400\u2013404. https:\/\/doi.org\/10.1038\/nrrheum.2009.106","journal-title":"Nat Rev Rheumatol"},{"key":"783_CR11","first-page":"2563","volume":"36","author":"E Aghdassi","year":"2009","unstructured":"Aghdassi E, Morrison S, Landolt-Marticorena C, Su J, Pineau C, Pope J, Peschken CA, Gladman DD, Urowitz MB, CaNIOS LuNNET Investigators Joan Wither and Paul R Fortin (2009) Quality of life in lupus patients with and without renal involvement. J Rheumatol 36:2563","journal-title":"J Rheumatol"},{"key":"783_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3349\/ymj.2018.59.7.857","volume":"59","author":"SK Kim","year":"2018","unstructured":"Kim SK, Choe JY, Lee SS (2018) Self-reported physical activity is associated with lupus nephritis in systemic lupus erythematosus: data from KORean Lupus Network (KORNET) registry. Yonsei Med J 59:857\u2013864. https:\/\/doi.org\/10.3349\/ymj.2018.59.7.857","journal-title":"Yonsei Med J"},{"key":"783_CR13","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2147\/ppa.S111725","volume":"10","author":"N Mozaffarian","year":"2016","unstructured":"Mozaffarian N, Lobosco S, Lu P, Roughley A, Alperovich G (2016) Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives. Patient Prefer Adherence 10:2051\u20132061. https:\/\/doi.org\/10.2147\/ppa.S111725","journal-title":"Patient Prefer Adherence"},{"key":"783_CR14","doi-asserted-by":"publisher","first-page":"A84","DOI":"10.1136\/lupus-2019-lsm.114","volume":"6","author":"JL Rogers","year":"2019","unstructured":"Rogers JL, Eudy AM, Criscione-Schreiber LG, Pisetsky DS, Doss J, Sun K, Clowse ME (2019) Features of fibromyalgia in lupus nephritis. Lupus Sci Med 6:A84\u2013A86. https:\/\/doi.org\/10.1136\/lupus-2019-lsm.114","journal-title":"Lupus Sci Med"},{"key":"783_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.22881","volume":"57","author":"K McElhone","year":"2007","unstructured":"McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, Peers K, Isenberg D, Ferenkeh-Koroma A, Griffiths B, Akil M, Maddison P, Teh LS (2007) Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 57:972\u2013979. https:\/\/doi.org\/10.1002\/art.22881","journal-title":"Arthritis Rheum"},{"key":"783_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40744-021-00292-1","volume":"8","author":"K Raymond","year":"2021","unstructured":"Raymond K, Park J, Joshi AV, White MK (2021) Patient experience with fatigue and qualitative interview-based evidence of content validation of the FACIT-fatigue in systemic lupus erythematosus. Rheumatol Ther 8:541\u2013554. https:\/\/doi.org\/10.1007\/s40744-021-00292-1","journal-title":"Rheumatol Ther"},{"key":"783_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1177\/0961203313476360","volume":"22","author":"M Kosinski","year":"2013","unstructured":"Kosinski M, Gajria K, Fernandes AW, Cella D (2013) Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus 22:422\u2013430. https:\/\/doi.org\/10.1177\/0961203313476360","journal-title":"Lupus"},{"key":"783_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3899\/jrheum.100799","volume":"38","author":"JS Lai","year":"2011","unstructured":"Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D (2011) Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol 38:672\u2013679. https:\/\/doi.org\/10.3899\/jrheum.100799","journal-title":"J Rheumatol"},{"key":"783_CR19","doi-asserted-by":"publisher","first-page":"e000373","DOI":"10.1136\/lupus-2019-000373","volume":"7","author":"V Strand","year":"2020","unstructured":"Strand V, Simon LS, Meara AS, Touma Z (2020) Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. Lupus Sci Med 7:e000373. https:\/\/doi.org\/10.1136\/lupus-2019-000373","journal-title":"Lupus Sci Med"},{"key":"783_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/09612033221145634","volume":"32","author":"L Moroni","year":"2023","unstructured":"Moroni L, Mazzetti M, Ramirez GA, Zuffada S, Ciancio A, Gallina G, Farina N, Bozzolo E, Di Mattei V, Dagna L (2023) Post-traumatic stress disorder in patients with systemic lupus erythematosus heavily affects quality of life. A cross-sectional web survey-based study. Lupus 32:263\u2013269. https:\/\/doi.org\/10.1177\/09612033221145634","journal-title":"Lupus"},{"key":"783_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/rheumatology\/keaa453","volume":"60","author":"A Gomez","year":"2020","unstructured":"Gomez A, Hani Butrus F, Johansson P, \u00c5kerstr\u00f6m E, Soukka S, Emamikia S, Enman Y, Pettersson S, Parodis I (2020) Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology 60:1260\u20131272. https:\/\/doi.org\/10.1093\/rheumatology\/keaa453","journal-title":"Rheumatology"},{"key":"783_CR22","unstructured":"FACIT.org FACIT-F (2024) Functional assessment of chronic illness therapy\u2013 Fatigue. https:\/\/www.facit.org\/measures\/facit-f. Accessed May 2024"},{"key":"783_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s41687-021-00298-x","volume":"5","author":"R Rendas-Baum","year":"2021","unstructured":"Rendas-Baum R, Baranwal N, Joshi AV, Park J, Kosinski M (2021) Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). J Patient Rep Outcomes 5:33. https:\/\/doi.org\/10.1186\/s41687-021-00298-x","journal-title":"J Patient Rep Outcomes"},{"key":"783_CR24","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.22881","volume":"57","author":"K McElhone","year":"2007","unstructured":"McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, Peers K, Isenberg D, Ferenkeh-Koroma A, Griffiths B, Akil M, Maddison P, Teh L-s (2007) Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Care Res 57:972\u2013979. https:\/\/doi.org\/10.1002\/art.22881","journal-title":"Arthritis Care Res"},{"key":"783_CR25","unstructured":"U.S. National Library of Medicine (2018) Treatment of lupus nephritis with allogeneic mesenchymal stem cells (MSV_LE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03673748. Accessed June 2023"},{"key":"783_CR26","unstructured":"U.S. National Library of Medicine (2022) Study of efficacy and safety of LNP023 in participants with active lupus nephritis class III-IV, +\/- V. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05268289. Accessed June 2023"},{"key":"783_CR27","unstructured":"U.S. National Library of Medicine (2019) Study of safety, efficacy and tolerability of secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis (SELUNE). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04181762. Accessed June 2023"},{"key":"783_CR28","unstructured":"FDA (2022) Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessment. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 15 May 2024"},{"key":"783_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.sapharm.2018.03.066","volume":"15","author":"E Almanasreh","year":"2019","unstructured":"Almanasreh E, Moles R, Chen TF (2019) Evaluation of methods used for estimating content validity. Res Soc Adm Pharm 15:214\u2013221. https:\/\/doi.org\/10.1016\/j.sapharm.2018.03.066","journal-title":"Res Social Administrative Pharm"},{"key":"783_CR30","unstructured":"US Food and Drug Administration (2009) Patient-reported outcome measures: use in Medical Product Development to support labeling claims-Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"key":"783_CR31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L (2011) Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Value Health 14:967\u2013977. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014","journal-title":"Value Health"},{"key":"783_CR32","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L (2011) Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2\u2014assessing respondent understanding. Value Health 14:978\u2013988. https:\/\/doi.org\/10.1016\/j.jval.2011.06.013","journal-title":"Value Health"},{"key":"783_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/ard.2007.086009","volume":"68","author":"LC Doward","year":"2009","unstructured":"Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ (2009) The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 68:196\u2013200. https:\/\/doi.org\/10.1136\/ard.2007.086009","journal-title":"Ann Rheum Dis"},{"key":"783_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40744-021-00374-0","volume":"9","author":"S Cleanthous","year":"2022","unstructured":"Cleanthous S, Strzok S, Haier B, Cano S, Morel T (2022) The patient experience of fatigue in systemic lupus erythematosus: a conceptual model. Rheumatol Ther 9:95\u2013108. https:\/\/doi.org\/10.1007\/s40744-021-00374-0","journal-title":"Rheumatol Ther"},{"key":"783_CR35","doi-asserted-by":"publisher","unstructured":"Williams-Hall R, Berry P, Williamson N, Barclay M, Roberts A, Gater A, Tolley C, Bradley H, Ward A, Hsia E, Zuraw Q, DeLong P, Touma Z, Strand V (2022) Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN). Lupus Sci Med 9. https:\/\/doi.org\/10.1136\/lupus-2022-000712","DOI":"10.1136\/lupus-2022-000712"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00783-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00783-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00783-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T13:02:18Z","timestamp":1727701338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00783-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00783-z","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All recruitment, screening and consenting activities were pre-approved by the relevant Institutional Review Boards (approval reference numbers: Pro00107074-INIT-1.0\u2009+\u2009Pro00107074-AMD-2.0; i20-00668; SSU00133803; 20-08-549-031; SSU00136017). All data were kept strictly confidential in accordance with local, state, and federal regulations and International Council for Harmonisation Good Clinical Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MLM is an employee of Evidera, a company contracted by GSK to carry out this study. JNH was an employee of Evidera, a company contracted by GSK to carry out this study, at the time of the study. DC is an employee of GSK and holds financial equities in GSK. KG and W-HC were employees of GSK at the time of the study and hold financial equities in GSK. JLR has nothing to disclose pertaining to the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}